CHMP Positive on Novartis' Votubia - Analyst Blog
24 September 2012 - 11:28PM
Zacks
Switzerland-based pharmaceutical company, Novartis
AG (NVS) recently announced that the Committee for
Medicinal Products for Human Use (CHMP) of the European Medicines
Agency (EMA) gave a positive opinion on Votubia (everolimus) for
the treatment of patients suffering from renal angiomyolipoma,
associated with tuberous sclerosis complex (TSC).
On approval, the drug can be used in patients who are at risk of
complications such as tumor size or in the presence of aneurysm or
multiple or bilateral tumors but at the same time who do not
require immediate surgery.
Novartis’ Votubia enjoys orphan drug status in the EU for TSC.
EU approval would make Votubia the first non-surgical treatment
alternative for patients diagnosed with kidney tumors associated
with TSC.
According to data from National Institute of Neurological
Disorders and Stroke, kidney tumors, or renal angiomyolipomas, are
found to affect up to 80% of patients with TSC and the increase in
tumor size can be life-threatening.
The favorable recommendation was based on data from a phase III
study, EXIST-2, which showed that 42% of patients treated with
Votubia experienced a response in angiomyolipoma compared to 0% of
patients on placebo.
We note Votubia is currently approved as Afinitor in the US for
the treatment of patients suffering from renal angiomyolipoma,
which is associated with TSC and not requiring immediate
surgery.
Votubia is also approved as Afinitor in the US and EU for the
treatment of advanced renal cell carcinoma (kidney cancer) after
the failure of treatment with Pfizer Inc.’s (PFE)
Sutent (sunitinib) or Onyx Pharmaceuticals, Inc.’s
(ONXX) Nexavar (sorafenib).
In July 2012, Novartis’ Afinitor gained approval both in the US
and the EU for the treatment of HR+ HER2- advanced breast cancer in
combination with exemestane, after the failure of treatment with
Femara (letrozole) or AstraZeneca’s (AZN) Arimidex
(anastrozole).
We note that Novartis recorded Afinitor sales of $175 million in
the second quarter of 2012.
Our Recommendation
Currently, we have a Neutral recommendation on Novartis. The
company carries a Zacks #3 Rank (Hold rating) in the short run.
ASTRAZENECA PLC (AZN): Free Stock Analysis Report
NOVARTIS AG-ADR (NVS): Free Stock Analysis Report
ONYX PHARMA INC (ONXX): Free Stock Analysis Report
PFIZER INC (PFE): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Onyx Pharmaceuticals, Inc. (MM) (NASDAQ:ONXX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Onyx Pharmaceuticals, Inc. (MM) (NASDAQ:ONXX)
Historical Stock Chart
From Jul 2023 to Jul 2024